<DOC>
	<DOCNO>NCT02880956</DOCNO>
	<brief_summary>This study seek evaluate efficacy safety ABBV-8E12 subject Early Alzheimer 's Disease .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ABBV-8E12 Subjects With Early Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Subject meet National Institute Aging Alzheimer 's Association ( NIAAA ) clinical criterion mild cognitive impairment probable AD , : Clinical Dementia Rating ( CDR ) Global Score 0.5 MiniMental State Examination ( MMSE ) score 22 30 , inclusive Repeatable Battery Assessment Neuropsychological StatusDelayed Memory Index ( RBANS DMI ) score 85 low Subject positive amyloid Positron Emission Tomography ( PET ) scan . Subject Modified Hachinski Ischemic Scale ( MHIS ) score â‰¤ 4 . The subject identify , reliable , study partner ( e.g. , family member ) . If use medication treat symptom related AD , dose must stable least 12 week prior randomization . Subject contraindication inability tolerate brain magnetic resonance imaging ( MRI ) , PET scan lumbar puncture . Subject evidence clinically significant neurological disorder Early AD . In opinion investigator , subject clinically significant uncontrolled medical psychiatric illness , infection require medical intervention past 30 day . Subject myocardial infarction , unstable angina , stroke , transient ischemic attack require intervention condition within 6 month Screening .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tau</keyword>
	<keyword>Nervous system disease</keyword>
	<keyword>Memory loss</keyword>
	<keyword>Mild Alzheimer 's Disease ( AD )</keyword>
	<keyword>Early Alzheimer 's Disease</keyword>
	<keyword>Early dementia</keyword>
	<keyword>Mild Cognitive Impairment ( MCI )</keyword>
	<keyword>AD</keyword>
	<keyword>Tauopathies</keyword>
	<keyword>Neurodegenerative disease</keyword>
</DOC>